Gain Therapeutics to Present at 2026 Maxim Growth Summit

Event summary

Gain Therapeutics will attend the 2026 Maxim Growth Summit from October 12th to 14th in New York City.
The company will meet with institutional investors and engage with senior Maxim research analysts.
Gain Therapeutics' lead drug candidate, rexaceract, is in a Phase 1b clinical trial for Parkinson's disease.
The company has multiple preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

The big picture

Gain Therapeutics' participation in the Maxim Growth Summit underscores its strategic focus on engaging with institutional investors to support its clinical-stage biotechnology advancements. The company's lead drug candidate, rexaceract, and its Magellan™ platform position it within the competitive landscape of allosteric therapies, aiming to address neurodegenerative diseases and rare genetic disorders. The event provides a platform to showcase its pipeline and attract potential collaborators or investors.

What we're watching

Clinical Progress: The pace at which Gain Therapeutics advances rexaceract through Phase 1b and into Phase 2 trials will determine its near-term valuation.
Investor Sentiment: Whether the company can leverage the Maxim Growth Summit to attract significant institutional investor interest and secure potential partnerships.
Pipeline Development: How Gain Therapeutics' undisclosed preclinical assets progress, particularly in targeting lysosomal storage disorders and solid tumors.